vVARDIS Hits Unicorn Status with Apollo Backing

A Swiss company selling $80 toothpaste just became worth more than a billion dollars. vVARDIS, the Zurich-based luxury oral care brand, announced Tuesday it has achieved unicorn status following a strategic investment from Apollo Global Management, one of the world's largest alternative asset managers. The deal marks Apollo's latest move into the premium consumer goods sector and validates what vVARDIS has been arguing for years: there's real money in selling basic hygiene at luxury price points.

The investment amount wasn't disclosed — vVARDIS is still private, so the opacity is expected — but the company confirmed the round values it north of $1 billion. That puts it in rarefied territory for a brand most people outside Zurich's wealth management districts have never heard of. Apollo led the round with participation from existing investors including Swiss private equity firm Capvis and family offices across Europe.

Founded in 2018 by Dr. Haleh Moravej, an Iranian-born dentist who built her practice serving ultra-high-net-worth clients in Switzerland, vVARDIS entered the market with a thesis that sounds absurd until you look at the margins: oral care is underpriced relative to skincare, and the same consumers buying $300 face creams will pay $80 for toothpaste if you give them the right story. Turns out, they will.

The brand's hero product — a whitening toothpaste called White Enamel — retails for 85 Swiss francs (roughly $95 at current exchange rates) per tube. It's positioned as a prestige alternative to mass-market whitening treatments, formulated with what the company calls "biomimetic" ingredients that mirror natural tooth enamel. Whether that's materially different from what Colgate puts in a $6 tube is a question for chemists, but vVARDIS isn't selling to people who comparison-shop ingredients labels.

Apollo's interest makes sense when you map it against the firm's recent consumer portfolio moves. Over the past three years, Apollo has quietly built positions in several premium personal care and beauty brands, including stakes in Natura &Co and investments in fragrance and skincare rollups across Europe and North America. The thesis is consistent: find categories where commoditized products can be repositioned at 10x-20x markups with the right branding, then scale through direct-to-consumer channels and selective retail partnerships.

Oral care fits that framework perfectly. The global oral care market is worth roughly $50 billion annually, dominated by Procter & Gamble, Colgate-Palmolive, and Unilever — massive players with razor-thin margins selling volume at low price points. Premium oral care is a sliver of that, but it's growing faster and generating margins in the 60-70% range compared to 15-20% for mass-market toothpaste.

"We see vVARDIS as part of a broader premiumization trend in categories that have been historically commodity-driven," said a spokesperson for Apollo in a statement. "Consumers, particularly in high-income demographics, are willing to pay significantly more for products that deliver both functional and emotional value."

Translation: rich people will overpay for toothpaste if you make them feel like they're not overpaying for toothpaste. It's the entire luxury playbook, applied to a product category that hasn't traditionally had a luxury tier.

vVARDIS started in Moravej's dental clinic, where she noticed her wealthiest clients were using the same drugstore toothpaste as everyone else despite spending tens of thousands on cosmetic dentistry. She developed a proprietary formula — initially just for her practice — and began selling it to patients. Word spread through Switzerland's tight circles of wealth managers, private bankers, and family office principals. By 2019, she'd formalized vVARDIS as a standalone brand.

The early growth was almost entirely word-of-mouth and referral-driven. vVARDIS didn't advertise. It sold through its own site and a handful of ultra-premium Swiss pharmacies. The brand leaned into scarcity as a feature — limited production runs, invitation-only purchasing for certain products, collaborations with high-end hotels and spas. It worked. Revenue in the first full year was around $2 million. By 2023, it had crossed $50 million.

Capvis came in with a minority stake in early 2024, providing capital to expand into the U.S. and Middle East. The brand opened concessions in Harrods, Bergdorf Goodman, and several luxury hotels including Aman properties and the Bürgenstock Resort. It launched a subscription model for its core whitening system — $240 every three months — and added adjacent products: mouthwash, floss, and a $1,200 electric toothbrush with interchangeable heads plated in rose gold.

Revenue last year hit approximately $120 million, according to sources familiar with the financials. Gross margins are estimated north of 65%. Customer acquisition cost is low relative to revenue per customer — the brand doesn't do paid social or traditional advertising. It relies on influencer seeding (mostly micro-influencers in wealth management and wellness circles), PR placements in luxury lifestyle media, and organic referrals from existing customers.

The business model is elegant in its simplicity: sell a consumable product with high repeat purchase rates to a narrow but deep customer base. The average vVARDIS customer spends over $800 annually. Retention is above 70% year-over-year. The brand isn't chasing mass-market scale — it's chasing lifetime value per customer, and in that metric, it's outperforming most DTC brands.

vVARDIS isn't alone in this space anymore. Competitors have emerged over the past few years, including Marvis (the Italian toothpaste brand now owned by Ludovico Martelli), Selahatin (a Swedish luxury oral care line), and Apa Beauty (founded by celebrity dentist Dr. Michael Apa). None have crossed the $1 billion valuation threshold, but the category is clearly attracting both capital and competition.

The playbook here is fairly standard for Apollo's consumer investments: inject capital, professionalize operations, scale distribution, then exit in 3-5 years either through a sale to a strategic buyer or an IPO. The most likely acquirers would be the major beauty conglomerates — Estée Lauder, L'Oréal, LVMH, or Unilever's Prestige division — all of which have been actively acquiring premium personal care brands to offset slowing growth in their legacy mass-market portfolios.

In the near term, expect vVARDIS to expand its product line (skincare-meets-oral-care hybrids are likely, given the overlap in ingredient science and customer demographics), open standalone retail locations in key cities (Tokyo, New York, Dubai are obvious targets), and push deeper into Asia-Pacific, where demand for Western luxury personal care is still growing in the high single digits annually.

There's also likely to be a wholesale distribution expansion. Right now, vVARDIS is in fewer than 50 physical retail locations globally. Apollo will push that number into the hundreds, targeting luxury department stores, high-end pharmacies (the European "parapharmacie" model), and five-star hotel partnerships. The brand has been deliberately scarce; Apollo will make it selectively accessible, which is a delicate balance but one the firm has managed before with other prestige brands.

Dr. Moravej remains CEO and retains a significant equity stake, according to the announcement. That continuity matters — founder-led brands in the luxury space tend to lose their edge when the founder exits too early. Apollo is betting she can scale without diluting the brand's positioning, which is harder than it sounds.

The biggest threat to vVARDIS isn't competition from other luxury oral care brands — it's overexpansion. Luxury is partially a function of exclusivity, and exclusivity breaks down when the product becomes too available. If vVARDIS toothpaste ends up in every Sephora and duty-free shop, it stops being a status signal and starts being just expensive toothpaste.

Apollo is aware of this dynamic — it's dealt with it before in fragrance and spirits. The strategy is usually to create tiered product lines: keep the hero products selective and premium, then introduce lower-priced entry products (a $30 toothpaste instead of $80, for example) that expand the customer base without cannibalizing the prestige tier. Whether that works for oral care, where the product itself is identical in function to a $5 alternative, remains to be seen.

Step back, and this deal is part of a larger pattern. Private equity has been pouring capital into premium and ultra-premium consumer goods for the past five years, especially in categories that were historically commodity-driven. We've seen it in coffee (Blue Bottle, acquired by Nestlé but initially PE-backed), in sparkling water (Topo Chico, bought by Coca-Cola), in oat milk (Oatly's IPO), and now in toothpaste.

The logic is the same across all these deals: find a low-margin category, identify a subsegment of consumers willing to pay a massive premium for perceived quality or status, build a brand that captures that subsegment, then scale it just enough to hit a valuation that makes the exit attractive. It's arbitrage on consumer psychology.

What's notable about vVARDIS specifically is how far up-market the product is priced relative to the category baseline. A $95 tube of toothpaste isn't 2x or 3x the price of a premium alternative — it's 15x-20x the price of a standard tube. That's a bigger gap than you see in most premiumization plays, which suggests either exceptional margin opportunity or exceptional risk of market resistance. Apollo is betting on the former.

The comps are instructive. In skincare, brands like La Mer and Sisley charge 20x-30x what mass-market moisturizers cost, and they've sustained that premium for decades. In oral care, no brand has successfully held that kind of pricing power at scale — yet. vVARDIS is the test case for whether oral care can follow skincare's playbook.

Let's be clear about what's actually being sold here. The cost of goods for a tube of premium toothpaste — even with high-quality ingredients, Swiss manufacturing, and luxury packaging — is probably in the $8-$12 range. vVARDIS is selling it for $85-$95, which means the gross margin is 85-90%. After you account for customer acquisition, logistics, retail commissions (when applicable), and overhead, you're still looking at operating margins in the 40-50% range if the business is run efficiently.

Compare that to a mass-market oral care company, where gross margins are 20-25% and operating margins are often sub-10%. The unit economics are radically different, which is why PE firms are interested despite the smaller addressable market. You don't need to sell a billion tubes — you need to sell a million tubes to the right people.

If you're skeptical that anyone would pay $95 for toothpaste, you're not wrong to be skeptical — most people won't. But most people don't matter to vVARDIS's business model. What matters is that a small, identifiable, reachable segment of high-income consumers will pay it, and that segment is large enough to support a billion-dollar business.

This is where consumer behavior gets interesting. Luxury isn't rational. People buy $1,000 sneakers that cost $30 to make, $500 candles, $200 water bottles. The product's functional value is almost irrelevant — what's being purchased is identity signaling, aesthetic cohesion, or just the subjective experience of using something that feels premium. vVARDIS sells all three.

The brand's packaging is museum-quality — minimalist, heavy, tactile. The product itself has a distinct texture and flavor profile that's immediately recognizable as different from drugstore paste. And the price creates its own halo: if you're spending $95 on toothpaste, you're signaling (to yourself if no one else) that you prioritize quality, that you can afford not to compromise, that you're the kind of person who optimizes even the smallest details of daily life.

Whether that's worth the premium is subjective. Whether enough people believe it's worth the premium to justify a unicorn valuation is apparently no longer in question.

vVARDIS isn't operating in a vacuum. The luxury oral care space has gotten noticeably more crowded in the past two years. Here's how the landscape breaks down.

vVARDIS is at the very top of this spectrum, both in price and revenue scale. Its closest competitor in positioning is probably Theodent, which also sells a $100 toothpaste based on proprietary ingredient science, but Theodent has struggled to gain traction beyond a niche wellness audience. Selahatin and Marvis are more accessible and design-focused — they're premium, but not ultra-premium. Apa Beauty has celebrity backing but hasn't translated that into significant revenue yet.

What vVARDIS has that the others don't is a coherent brand universe and a customer base with extraordinary spending power. It's not competing with Marvis for the design-conscious consumer who wants a prettier tube in their bathroom. It's competing with high-end skincare for wallet share among people who spend $5,000+ annually on personal care products. That's a different game.

In the immediate term, expect vVARDIS to use the Apollo capital to accelerate U.S. expansion. The American market is underpenetrated relative to Europe and the Middle East, and it's where the biggest revenue growth opportunity sits. The brand will likely open a flagship store in New York (SoHo or Madison Avenue), expand its Bergdorf Goodman footprint, and push into Neiman Marcus and select Nordstrom locations.

Internationally, Asia-Pacific is the next frontier. Luxury oral care is already a thing in Japan and South Korea, where consumers are highly attuned to premium personal care and willing to pay for imported Western brands with strong science credentials. China is trickier — the luxury market there is slowing, and oral care specifically is still heavily tilted toward mass-market products — but it's too big to ignore.

Product line extensions are inevitable. vVARDIS will likely move into adjacent categories where the same customer base and brand equity apply: premium dental floss, whitening trays, possibly even supplements or ingestibles tied to oral health. Skincare collaboration or co-branding is also plausible — there's overlap in the ingredient science (hydroxyapatite, peptides, antioxidants) and the customer demographics.

The exit timeline is probably 3-5 years. Apollo will want to get vVARDIS to $250-$300M in revenue, prove that the model works across multiple geographies and channels, then shop it to the big beauty conglomerates. Estée Lauder bought Le Labo and Deciem. L'Oréal bought CeraVe and Valentino Beauty. LVMH owns Sephora and Fenty. There's precedent for a $2-3 billion acquisition of a scaled premium personal care brand, and that's the endgame here.